Novel targeted therapies for eosinophilic disorders

Wechsler, Michael E; Fulkerson, Patricia C; Bochner, Bruce S; Gauvreau, Gail M; Gleich, Gerald J; Henkel, Tim; Kolbeck, Roland; Mathur, Sameer K; Ortega, Hector; Patel, Jatin; Prussin, Calman; Renzi, Paolo; Rothenberg, Marc E; Roufosse, Florence; Simon, Dagmar; Simon, Hans-Uwe; Wardlaw, Andrew; Weller, Peter F; Klion, Amy D (2012). Novel targeted therapies for eosinophilic disorders. Journal of allergy and clinical immunology, 130(3), pp. 563-71. St. Louis, Mo.: Mosby 10.1016/j.jaci.2012.07.027

Full text not available from this repository.

Hypereosinophilic syndromes (HESs) are a diverse group of conditions characterized by clinical manifestations attributable to eosinophilia and eosinophilic infiltration of tissues. HESs are chronic disorders with significant morbidity and mortality. Although the availability of targeted chemotherapeutic agents, including imatinib, has improved quality of life and survival in some patients with HESs, additional agents with increased efficacy and decreased toxicity are sorely needed. The purpose of this review is to provide an overview of eosinophil biology with an emphasis on potential targets of pharmacotherapy and to provide a summary of potential eosinophil-targeting agents, including those in development, in clinical trials, or approved for other disorders.

Item Type:	Journal Article (Further Contribution)
Division/Institute:	04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology 04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology
UniBE Contributor:	Simon, Dagmar, Simon, Hans-Uwe
ISSN:	0091-6749
Publisher:	Mosby
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 14:35
Last Modified:	05 Dec 2022 14:11
Publisher DOI:	10.1016/j.jaci.2012.07.027
PubMed ID:	22935585
Web of Science ID:	000308463500001
URI:	https://boris.unibe.ch/id/eprint/14105 (FactScience: 220914)